Mind Medicine (Mind Medicine) EBIT per Share : $0.00 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mind Medicine EBIT per Share?

Mind Medicine's EBIT per Share for the three months ended in Mar. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

During the past 3 years, the average EBIT per Share Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Mind Medicine's EBIT per Share or its related term are showing as below:

MMCWF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -8.8 Med: -8.8 Max: -8.8
Current: -8.8

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Mind Medicine was -8.80% per year. The lowest was -8.80% per year. And the median was -8.80% per year.

MMCWF's 3-Year EBIT Growth Rate is ranked worse than
64.67% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs MMCWF: -8.80

Mind Medicine's EBIT for the three months ended in Mar. 2024 was $-53.97 Mil.

Mind Medicine EBIT per Share Historical Data

The historical data trend for Mind Medicine's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine EBIT per Share Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-	-	-	-	-

Mind Medicine EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Mind Medicine's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-93.866	/	0
=	N/A

Mind Medicine's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-53.966	/	0
=	N/A

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

Mind Medicine (OTCPK:MMCWF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Mind Medicine EBIT per Share Related Terms

Thank you for viewing the detailed overview of Mind Medicine's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMCWF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.